If drugs acting on amyloid and tau can defy the sector’s history of failure, the testing landscape will change dramatically.
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.